Premium
Hypertension Induced by Tyrosine‐Kinase Inhibitors for the Treatment of Renal Cell Carcinoma in Hemodialysis Patients: A Single‐Center Experience and Review of the Literature
Author(s) -
Nakai Kentaro,
Fujii Hideki,
Kono Keiji,
Goto Shunsuke,
Nishi Shinichi
Publication year - 2017
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.12537
Subject(s) - medicine , renal cell carcinoma , hemodialysis , tyrosine kinase , tyrosine kinase inhibitor , dialysis , malignancy , blood pressure , gastroenterology , urology , oncology , pharmacology , cancer , receptor
Malignancy is a major cause of mortality in dialysis patients. Although molecular‐targeted anticancer drugs, including tyrosine‐kinase inhibitors, are used for advanced renal cell carcinoma treatment, there are few reports on their effectiveness and safety in dialysis patients. Renal cell carcinoma dialysis patients treated at our hospital from 2010 to 2013 participated in this study. Thirteen patients were treated with tyrosine‐kinase inhibitors and 15 patients with surgery only (control group). During treatment, blood pressure changes and dry weight reduction tended to be greater in the tyrosine‐kinase inhibitor group than in controls. More intensive management of hypertension was necessary in the tyrosine‐kinase inhibitor group than in the controls. Renal cell carcinoma treatment by tyrosine‐kinase inhibitors increased blood pressure in hemodialysis patients. We should prevent and manage hypertension carefully by adjusting antihypertensive drugs and dry weight in renal cell carcinoma patients.